aTyr Pharma, Inc.
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.3 | 4.8 | 3.6 | 3.9 | – | – | – | – | – | – | – | – | – | – | 8.6 | 235.0 | 224.8 | 196.7 | 580.6 | 1,267.3 | – | – | 368.2 | 402.4 | 402.5 | 308.1 | |
| 1.0 | 0.8 | 1.6 | 2.0 | 1.8 | 1.6 | 1.5 | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 | 0.8 | 0.5 | 1.1 | 1.0 | 1.3 | 1.3 | 1.9 | 1.4 | 1.9 | 1.5 | 0.9 | 1.1 | 0.9 | 0.8 | 1.1 | 0.9 | 0.9 | 1.6 | 1.4 | 2.1 | 4.3 | 3.5 | 6.1 | 0.9 | 1.1 | 1.3 | 1.2 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.5 | 3.0 | 1.9 | 2.4 | – | – | – | – | – | – | – | – | – | – | 7.8 | 174.9 | 215.1 | 187.1 | 537.0 | 1,225.6 | – | – | 343.3 | 353.5 | 357.6 | 230.8 | |
| -68.1% | -102.5% | -66.0% | -62.2% | -34.1% | -41.9% | -50.5% | -147.6% | -154.0% | -208.8% | -142.9% | -132.1% | -148.4% | -122.9% | -63.1% | -33.4% | -48.8% | -37.6% | -36.6% | -31.1% | -18.5% | -16.0% | -25.0% | -49.6% | -46.7% | -68.0% | -40.0% | -33.3% | -40.9% | -45.1% | -43.9% | -55.4% | -49.2% | -23.2% | -24.0% | -12.1% | -90.1% | -81.2% | -77.5% | -93.6% | |
| Margins | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | 71.8% | -676.5% | -237.8% | -203.2% | -401.3% | -5,431.5% | – | – | -18,388.4% | -12,160.0% | -12,165.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -179.6% | -185.5% | -198.1% | -152.2% | – | – | – | – | – | – | – | – | – | – | -436.8% | -15,557.8% | -9,994.6% | -10,633.5% | -28,958.7% | -28,899.6% | – | – | -41,395.3% | -40,856.3% | -38,573.7% | -33,609.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -185.1% | -190.1% | -202.0% | -155.2% | – | – | – | – | – | – | – | – | – | – | -401.8% | -14,274.5% | -9,171.6% | -9,846.4% | -27,155.7% | -27,243.8% | – | – | -39,537.9% | -39,009.5% | -36,857.4% | -32,003.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -143.4% | -160.4% | -176.2% | -148.3% | – | – | – | – | – | – | – | – | – | – | -352.4% | -10,605.1% | -9,863.4% | -10,892.7% | -28,555.7% | -29,440.0% | – | – | -33,154.2% | -32,664.7% | -31,209.5% | -28,852.1% | |
| Returns | ||||||||||||||||||||||||||||||||||||||||
| -83.5% | -92.1% | -108.8% | -129.7% | -68.2% | -75.0% | -83.4% | -96.4% | -101.7% | -102.6% | -101.7% | -84.1% | -89.6% | -111.4% | -37.3% | -45.2% | -53.7% | -51.3% | -50.6% | -71.0% | -25.6% | -30.9% | -39.3% | -47.1% | -60.1% | -63.4% | -41.1% | -42.4% | -43.9% | -55.6% | -63.8% | -70.9% | -97.7% | -91.4% | -84.5% | -89.0% | -93.6% | -109.8% | -120.9% | -124.6% | |
| -71.9% | -71.8% | -83.9% | -84.5% | -52.2% | -53.9% | -57.9% | -64.0% | -66.4% | -65.4% | -60.1% | -52.1% | -54.8% | -65.2% | -28.9% | -34.3% | -41.5% | -41.9% | -45.6% | -59.3% | -24.3% | -29.2% | -37.0% | -42.5% | -48.3% | -47.3% | -33.0% | -33.9% | -34.5% | -41.8% | -47.6% | -54.7% | -69.7% | -66.1% | -65.2% | -65.6% | -70.4% | -78.7% | -87.9% | -87.1% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||||||||
| -32 | -38 | -28 | -33 | -27 | -16 | -15 | -12 | -24 | -15 | -4.5 | -6.0 | -8.8 | 0.3 | -32 | -16 | -14 | -16 | -12 | -1.3 | -59 | -1.4 | -7.3 | -7.5 | -18 | -9.1 | -20 | -11 | -8.6 | -21 | -5.7 | -5.6 | -10 | -9.8 | -9.1 | -16 | -4.7 | -9.3 | -8.5 | -15 | |
| 86.1% | 78.0% | 77.1% | 65.1% | 76.5% | 71.9% | 69.5% | 66.4% | 65.2% | 63.8% | 59.1% | 62.0% | 61.1% | 58.5% | 77.4% | 75.9% | 77.2% | 81.7% | 90.2% | 83.6% | 94.9% | 94.6% | 94.1% | 90.2% | 80.4% | 74.6% | 80.3% | 80.0% | 78.7% | 75.1% | 74.6% | 77.0% | 71.3% | 72.3% | 77.2% | 73.7% | 75.2% | 71.7% | 72.7% | 69.9% | |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Per Share | ||||||||||||||||||||||||||||||||||||||||
| -36.50 | -34.15 | -32.54 | -30.53 | -26.73 | -22.67 | -21.36 | -20.50 | -18.58 | -15.93 | -12.40 | -7.83 | -6.23 | -6.07 | -2.28 | -1.74 | -1.79 | -1.53 | -1.78 | -1.80 | -1.66 | -1.22 | -1.39 | -1.45 | -1.62 | -1.56 | -1.08 | -0.82 | -0.75 | -0.85 | -0.82 | -0.80 | -0.84 | -0.77 | -0.73 | -0.74 | -0.77 | -0.76 | -0.71 | -0.62 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.23 | 0.92 | 0.89 | 0.99 | – | – | – | – | – | – | – | – | – | – | 0.19 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 43.71 | 37.07 | 29.90 | 23.54 | 39.20 | 30.21 | 25.61 | 21.27 | 18.26 | 15.53 | 12.19 | 9.31 | 6.95 | 5.44 | 6.12 | 3.86 | 3.33 | 2.99 | 3.52 | 2.54 | 6.48 | 3.93 | 3.54 | 3.09 | 2.69 | 2.45 | 2.62 | 1.93 | 1.70 | 1.53 | 1.28 | 1.13 | 0.86 | 0.85 | 0.87 | 0.83 | 0.83 | 0.69 | 0.59 | 0.50 | |
| -30.53 | -31.56 | -32.32 | -29.62 | -24.37 | -20.54 | -19.08 | -18.80 | -17.46 | -14.61 | -11.00 | -6.84 | -5.20 | -5.16 | -1.77 | -1.47 | -1.56 | -1.47 | -1.65 | -1.53 | -1.68 | -1.20 | -1.35 | -1.39 | -1.40 | -1.49 | -0.84 | -0.73 | -0.65 | -0.63 | -0.88 | -0.89 | -0.89 | -0.84 | -0.72 | -0.62 | -0.65 | -0.63 | -0.60 | -0.56 | |
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.